RxDoctor Payments Data

Mushtaq Shah, MD

Gastroenterology · Greenbelt, MDNPI 1043396633

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 35.6% of the total.

$4,054in general payments, 2019–2025

Across 304 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$438
  • Cumberland Pharmaceuticals, Inc.$359
  • Takeda Pharmaceuticals U.S.A., Inc.$265
  • Johnson & Johnson$257
  • AbbVie$234
  • plus $1K from 17 others
$151,348in research payments, 2019–2025

Across 27 payments — averaging $5605.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$150K
  • Eli Lilly$857

What the payments were for

  • Food & beverage$3,79794%
  • Education$2446%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,054 in reported general payments places this provider in the 55th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$80,204
Medicare patients
245
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide63$59,504
Mesalamine40$19,085
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates134$7,379
Omeprazole189$3,501
Tenofovir Disoproxil Fumarate12$869
Pantoprazole Sodium42$824
Famotidine51$770
Dicyclomine Hcl28$712
Esomeprazole Magnesium23$533
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl23$323
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl16$250
Metronidazole12$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$234$59,50463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →